jiangsuhengrui
-
US FDA Rejects HLB’s Liver Cancer Drug for the Second TimeBig Tech 2025. 3. 21. 13:40
· FDA issues Complete Response Letter for HLB’s liver cancer drug. The U.S. Food and Drug Administration (FDA) has issued a second Complete Response Letter (CRL) to HLB, a South Korean biopharmaceutical company, regarding its New Drug Application (NDA) for a liver cancer treatment. The decision, announced by HLB Chairman Jin Yang-gon, centers on unresolved issues related to the manufacturing pro..